Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 7.12Morepen Laboratories Ltd demonstrates a mixed financial performance. The company shows exceptional solvency and growth, driven by minimal debt and robust expansion in revenue, profits, and assets. Profitability is also a strong point, with impressive returns on capital, equity, and assets, alongside healthy margins. However, efficiency in asset utilization is a concern, as indicated by lower turnover ratios and longer inventory holding periods. The company's liquidity is reasonable, though there are some weaknesses noted in cash flow management. Furthermore, financial metrics such as earnings per share, book value, and capital expenditure need attention. Overall, Morepen Laboratories exhibits solid financial health, but improvements in operational efficiency and financial management could further enhance its performance.
Health Score : 7.12Morepen Laboratories Ltd demonstrates a mixed financial performance. The company shows exceptional solvency and growth, driven by minimal debt and robust expansion in revenue, profits, and assets. Profitability is also a strong point, with impressive returns on capital, equity, and assets, alongside healthy margins. However, efficiency in asset utilization is a concern, as indicated by lower turnover ratios and longer inventory holding periods. The company's liquidity is reasonable, though there are some weaknesses noted in cash flow management. Furthermore, financial metrics such as earnings per share, book value, and capital expenditure need attention. Overall, Morepen Laboratories exhibits solid financial health, but improvements in operational efficiency and financial management could further enhance its performance.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
85.66
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
59.91
P/B RATIO
4.55
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
3.06
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
32.54
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹103.65 as on Sep 1, 2026.
Growth Score : 10.00The company demonstrates excellent growth across various metrics. Revenue, operating profit, EPS, asset, and net income growth rates are all strong, reflecting the company's robust expansion and increasing profitability. This indicates the company is effectively capitalizing on market opportunities and generating significant value for its stakeholders. The consistent positive growth trend suggests a promising outlook for future performance.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 30.22 | -8.34 | 19.18 | 7.22 | -0.33 |
| Operating Profit Growth Rate | 15.13 | -41.61 | 98.75 | 9.43 | -27.59 |
| Earnings Per Share (EPS) Growth | -1.39 | -64.32 | 147.37 | 14.36 | -19.53 |
| Asset Growth Rate | 24.71 | 3.74 | 16.49 | 37.51 | 8.89 |
| Net Income Growth Rate | 5.15 | -61.76 | 148.72 | 21.65 | -18.64 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 37.27 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 70.69 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Windlas Biotech Ltd | 7.52 | 32.03 | Neutral | 105.00 | 32.19 | 66.00 |
| 4 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.89 | Neutral | 98.00 | 43.88 | 88.00 |
| 5 | RPG Life Sciences Ltd | 7.12 | 37.20 | Neutral | 147.00 | 69.64 | 115.00 |
| 6 | Morepen Laboratories Ltd | 7.12 | 59.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 7 | Alembic Ltd | 7.06 | 8.00 | Undervalued | 90.00 | 4.85 | 317.00 |
| 8 | Syncom Formulations (India) Ltd | 6.92 | 24.78 | Neutral | 77.00 | 0.81 | 76.00 |
| 9 | Hester Biosciences Ltd | 6.54 | 33.64 | Neutral | 87.00 | 61.24 | 57.00 |
| 10 | Sigachi Industries Ltd | 6.49 | -14.82 | Neutral | 54.00 | -2.08 | -83.00 |
| 11 | SMS Pharmaceuticals Ltd | 5.94 | 33.82 | Neutral | 171.00 | 9.35 | 102.00 |
| 12 | Gufic BioSciences Ltd | 5.49 | 65.79 | Neutral | 151.00 | 6.30 | 64.00 |
| 13 | Dishman Carbogen Amcis Ltd | 5.38 | 29.23 | Neutral | 566.00 | -2.45 | 97.00 |
| 14 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 40.61 | Neutral | 269.00 | 4.69 | 138.00 |
| 15 | Indoco Remedies Ltd | 5.26 | -23.65 | Neutral | 142.00 | -0.61 | -99.00 |
| 16 | Solara Active Pharma Sciences Ltd | 4.34 | -313.88 | Neutral | 187.00 | -1.50 | -7.00 |
| 17 | NOVARTIND | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Morepen Laboratories Ltd. is an Indian pharmaceutical company engaged in the manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), finished dosage forms, home diagnostics, and consumer healthcare products. It focuses on therapeutic areas like cardiology, diabetes, pain management, and gastroenterology, serving both domestic and international markets under its 'Dr. Morepen' brand.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Morepen Laboratories Ltd's P/E ratio (TTM) is 85.66, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Morepen Laboratories Ltd's P/B ratio is 4.55, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Morepen Laboratories Ltd's P/S ratio is 3.06, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Morepen Laboratories Ltd's PEG ratio is 0.28.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Morepen Laboratories Ltd's EV/EBITDA ratio is 32.54.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Morepen Laboratories Ltd's ROE is 7.70%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Morepen Laboratories Ltd's ROA is 6.51%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Morepen Laboratories Ltd's ROCE is 8%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Morepen Laboratories Ltd's operating margin is 6.98%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Morepen Laboratories Ltd's net margin is 5.32%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Morepen Laboratories Ltd's current ratio is 2.35.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Morepen Laboratories Ltd's debt-to-equity ratio is 0.12.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Morepen Laboratories Ltd's interest coverage ratio is 8.50.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Morepen Laboratories Ltd's DPS is ₹0.21.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Morepen Laboratories Ltd's EPS is -19.53.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹103.65. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1984
Headquarters: New Delhi, Delhi
Core Offerings: Active Pharmaceutical Ingredients (APIs), Finished Dosages (Formulations), Home Diagnostics, Consumer Healthcare Products, Dietary Supplements
Stock Listing: NSE (MOREPENLAB), BSE (500288)
Promoter: Suri Family / Morepen Group
Morepen Laboratories Ltd. was incorporated in 1984. It established its first API plant in Parwanoo, Himachal Pradesh in 1992 and went public in 1993. The company expanded its R&D capabilities in 1997. In the 2000s, Morepen diversified into finished dosage forms, home diagnostics under the 'Dr. Morepen' brand, and a range of consumer healthcare products, growing its presence in both domestic and international markets.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Active Pharmaceutical Ingredients (APIs) | 44% | Operating Profit |
| Consumer Brands & Diagnostics (Dr. Morepen) | 34% | Operating Profit |
| Finished Dosages (Formulations) | 22% | Operating Profit |
Active Pharmaceutical Ingredients (APIs): Manufactures over 20 APIs including Loratadine, Montelukast, Atorvastatin, and Rosuvastatin, serving both domestic and international markets with USFDA, EUGMP, and other regulatory approvals.
Finished Dosages (Formulations): Develops and markets a wide range of branded formulations across various therapeutic areas such as cardiology, diabetes, pain management, and gastroenterology.
Consumer Healthcare & Diagnostics (Dr. Morepen): Offers a portfolio of popular OTC brands like Dr. Morepen, Burnol, and Lemolate, alongside home diagnostic devices such as glucometers and blood pressure monitors.
Mr. Sushil Suri - Chairman & Managing Director. He is the founder of Morepen Laboratories and has been pivotal in steering the company's strategic growth and diversification over several decades in the pharmaceutical sector.
Morepen Inc. (USA)
Morepen Inc. (Canada)
Bonus Issue in the ratio of 1:1 (one new equity share for every one existing share) on 21-Sep-2023.
The Morepen Laboratories Ltd share price today is ₹103.65 on NSE (MOREPENLAB), as of 26 Sept 2026.
As of 25 Sept 2026, Morepen Laboratories Ltd share price is ₹103.65, with previous close ₹103.65. Today's range is ₹103.65 to ₹103.65. The 52-week range is ₹33.05 to ₹126.80.
As of today, Morepen Laboratories Ltd's market cap is ₹5,519.36 crore (Mid Cap).
Morepen Laboratories Ltd's current P/E ratio is 85.66, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 34.
Morepen Laboratories Ltd's current P/B ratio is 4.55.
Morepen Laboratories Ltd's current dividend yield is 0.20%. Last dividend of ₹0.30 per share was declared on 15-Sep-2023.
Morepen Laboratories Ltd's EPS (TTM) is ₹-19.53.
Morepen Laboratories Ltd. is an Indian pharmaceutical company engaged in the manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), finished dosage forms, home diagnostics, and consumer healthcare products. It focuses on therapeutic areas like cardiology, diabetes, pain management, and gastroenterology, serving both domestic and international markets under its 'Dr. Morepen' brand.
Morepen Laboratories Ltd is promoted by Suri Family / Morepen Group, holding 35.65% as of 25 Sept 2026.
Morepen Laboratories Ltd is listed on NSE (MOREPENLAB) and BSE (500288). Its next quarterly results are expected on August 2024.
Current Ratio
